{"prompt": "['Product: MK-3475', '142', 'Protocol/Amendment No.: 604-09', '12.4 Common Terminology Criteria for Adverse Events Version 4.0', 'The descriptions and grading scales found in the revised NCI CTCAE 4.0 will be utilized for', 'AE reporting (http://ctep.cancer.gov/reporting/ctc.html).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '143', 'Protocol/Amendment No.: 604-09', '12.5 Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 Criteria for', 'Evaluating Response in Solid Tumors', 'A modification to RECIST Version 1.1* will be used in this study for subject management.', 'While either CT or MRI may be used utilized, as per RECIST 1.1, CT is the preferred', 'imaging technique in this study. Details are provided in the Image Acquisition Guidelines.', '* As published in the European Journal of Cancer:', 'New response evaluation criteria in solid tumours: revised RECIST guideline (Version 1.1).', 'Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck', 'S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij', 'J. New response evaluation criteria in solid tumors: Revised RECIST guideline (Version', '1.1). Eur J Cancer. 2009 Jan;45(2):228-247.', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '144', 'Protocol/Amendment No.: 604-09', '12.6 List of Abbreviations', 'Abbreviation/Term', 'Definition', '1L', 'first-line', '2L', 'second-line', 'ADA', 'anti-drug antibodies', 'AE', 'adverse event', 'AEOSI', 'adverse event of special interest', 'ALT', 'alanine aminotransferase', 'ANC', 'Absolute neutrophil count', 'ASaT', 'All Subjects as Treated', 'AST', 'aspartate aminotransferase', 'AUC', 'area under the plasma drug concentration time curve', '\u00df-HCG', 'beta-human chorionic gonadotropin', 'BCG', 'Bacillus Calmette-Gu\u00e9rin', 'BICR', 'blinded independent central review', 'BSA', 'body surface area', 'CBC', 'complete blood count', 'CI', 'confidence interval', 'Cmax', 'maximum concentration', 'CR', 'complete response', 'CrCl', 'creatinine clearance', 'CSF', 'colony-stimulating factors', 'CSR', 'clinical study report', 'CT', 'computed tomography', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CTLA-4', 'cytotoxic T-lymphocyte-associated protein 4', 'DL', 'dose level', 'DMC', 'Data Monitoring Committee', 'DNA', 'deoxyribonucleic acid', 'DOR', 'duration of response', 'ECG', 'electrocardiogram', 'ECIs', 'events of clinical interest', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}